Marc Steven Sabatine, M.D.
Co-Author
This page shows the publications co-authored by Marc Sabatine and Nicholas Marston.
Connection Strength
5.902
-
Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022 Mar 01; 7(3):250-256.
Score: 0.990
-
Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. Circulation. 2021 11 23; 144(21):1732-1734.
Score: 0.955
-
Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism". Circulation. 2020 10 27; 142(17):e264.
Score: 0.902
-
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020 05 19; 141(20):1600-1607.
Score: 0.866
-
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019 10 15; 140(16):1308-1317.
Score: 0.835
-
Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation. 2021 07 20; 144(3):249-251.
Score: 0.237
-
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med. 2021 02; 14(1):e003006.
Score: 0.229
-
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
Score: 0.226
-
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 11 21; 396(10263):1637-1643.
Score: 0.226
-
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol. 2020 11 01; 5(11):1255-1262.
Score: 0.226
-
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation. 2020 02 25; 141(8):616-623.
Score: 0.211
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.